MD Revolution Acquires NavCare to Expand Remote Patient Care Management Services

MD Revolution, a leading provider of remote care management and clinical services has acquired NavCare, a remote patient care services company specializing in comprehensive chronic care management (CCM).

The acquisition provides NavCare clients with enhanced clinical and patient management tools, patient engagement applications and bi-directional integrations. Direct patient care will continue to be delivered by the same teams as NavCare patients migrate to MD Revolution’s RevUp Care Management Platform. The expanded leadership team will support all clients.

MD Revolution has been at the forefront of remote health innovation since 2011, providing remote patient monitoring (RPM) and CCM to over 1,700 providers and 150,000 patients, collecting and evaluating over 19 million vital measurements through care delivery.

NavCare has been providing proactive and preventative health assessments, screenings, and vital tracking through connected remote monitoring devices, 24/7 Care Team support, and the NavCare Connect integrated health platform since 2008. NavCare is located in Augusta, Georgia.

“MD Revolution offers not only extensive experience but also the best technology platform, and proven SaaS offering, to serve our growing client base” said Rick Griffin, CEO, NavCare. “We share the same culture and desire to provide exceptional personalized care to our patients, along with maintaining the highest clinical standards.”

NavCare teams will become employees of MD Revolution. Chris MacInnis will become Chief Operating Officer of MD Revolution and Theresa Lantz will become Vice President of Client Success. They will Join Kyle Williams, CEO, Paul Huffman, VP of Sales and Marketing and Michael Moore, VP of Product Management to lead the combined teams.

“NavCare’s experience in hospitals and its track record with annual wellness visits (AWV) and transitional care management (TCM) aligns with our growth strategy,” said Kyle Williams, CEO, MD Revolution. “Our operations will allow for better scaling of services and our combined care delivery and account management teams will mean improved capabilities benefitting all of our clients.”

Williams said that this merger will lead to MD Revolution being able to offer greatly expanded service to clients and patients.

“With this new relationship, we look forward to continued growth as we expand our services to the marketplace,” Williams said.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version